Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'NEUROLEPTIC TREATMENT' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 285 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Erbagci, AB; Herken, H; Koyluoglu, O; Yilmaz, N; Tarakcioglu, M
      Serum IL-1 beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment

      MEDIATORS OF INFLAMMATION
    2. Webster, MJ; Weickert, CS; Herman, MM; Hyde, TM; Kleinman, JE
      Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia

      SCHIZOPHRENIA RESEARCH
    3. Scheepers, FE; de Wied, CCG; Pol, HEH; van de Flier, W; van der Linden, JA; Kahn, RS
      The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics

      NEUROPSYCHOPHARMACOLOGY
    4. Malone, RP; Cater, J; Sheikh, RM; Choudhury, MS; Delaney, MA
      Olanzapine versus haloperidol in children with autistic disorder: An open pilot study

      JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
    5. Dawson, NM; Hamid, EH; Egan, MF; Meredith, GE
      Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment

      SYNAPSE
    6. Schmitt, A; Maras, A; Braus, DF; Petroianu, G; Jatzko, A; Gattaz, WF
      Antipsychotics and phospholipid metabolism in schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    7. Labelle, A; Light, M; Dunbar, F
      Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    8. Schwarz, MJ; Muller, N; Riedel, M; Ackenheil, M
      The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms

      MEDICAL HYPOTHESES
    9. Gareri, P; Cotroneo, A; Marchisio, U; Curcio, M; De Sarro, G
      Risperidone in the treatment of behavioral disorders in elderly patients with dementia

      ARCHIVES OF GERONTOLOGY AND GERIATRICS
    10. Lee, JH; Woo, JI; Meltzer, HY
      Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia

      PSYCHIATRY RESEARCH
    11. Karoumi, B; Saoud, M; d'Amato, T; Rosenfeld, F; Denise, P; Gutknecht, C; Gaveau, V; Beaulieu, FE; Dalery, J; Rochet, T
      Poor performance in smooth pursuit and antisaccadic eye-movement tasks in healthy siblings of patients with schizophrenia

      PSYCHIATRY RESEARCH
    12. Hori, H; Ohmori, O; Shinkai, T; Kojima, H; Nakamura, J
      Association between three functional polymorphisms of dopamine D2 receptorgene and tardive dyskinesia in schizophrenia

      AMERICAN JOURNAL OF MEDICAL GENETICS
    13. Norman, RMG; Malla, AK
      Duration of untreated psychosis: a critical examination of the concept andits importance

      PSYCHOLOGICAL MEDICINE
    14. Sutor, B; Rummans, TA; Smith, GE
      Assessment and management of behavioral disturbances in nursing home patients with dementia

      MAYO CLINIC PROCEEDINGS
    15. Dean, B; Hussain, T; Scarr, E; Pavey, G; Copolov, DL
      Extended treatment with typical and atypical antipsychotic drugs - Differential effects on the densities of dopamine D-2-like and GABA(A) receptors in rat striatum

      LIFE SCIENCES
    16. Konradi, C; Heckers, S
      Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia

      BIOLOGICAL PSYCHIATRY
    17. Krieger, S; Lis, S; Gallhofer, B
      Cognitive subprocesses and schizophrenia. A. Reaction-time decomposition

      ACTA PSYCHIATRICA SCANDINAVICA
    18. Krieger, S; Lis, S; Gallhofer, B
      Cognitive subprocesses and schizophrenia. B. Maze tasks

      ACTA PSYCHIATRICA SCANDINAVICA
    19. Hutton, SB; Crawford, TJ; Gibbins, H; Cuthbert, I; Barnes, TRE; Kennard, C; Joyce, EM
      Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia

      PSYCHOPHARMACOLOGY
    20. Andreassen, OA; Meshul, CK; Moore, C; Jorgensen, HA
      Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration

      PSYCHOPHARMACOLOGY
    21. Sakai, K; Gao, XM; Tamminga, CA
      Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats

      PSYCHOPHARMACOLOGY
    22. Heresco-Levy, U
      N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade

      INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
    23. Parashos, IA; Xiromeritis, K; Zoumbou, V; Stamouli, S; Theodotou, R
      The problem of non-compliance in schizophrenia: Opinions of patients and their relatives. A pilot study

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    24. Teri, L
      Combined therapy: A research overview

      INTERNATIONAL PSYCHOGERIATRICS
    25. Hanzel, TE; Bauernfeind, JD; Kalachnik, JE; Harder, SR
      Results of barbiturate antiepileptic drug discontinuation on antipsychoticmedication dose in individuals with intellectual disability

      JOURNAL OF INTELLECTUAL DISABILITY RESEARCH
    26. Tandon, R; DeQuardo, JR; Taylor, SF; McGrath, M; Jibson, M; Eiser, A; Goldman, M
      Phasic and enduring negative symptoms in schizophrenia: biological markersand relationship to outcome

      SCHIZOPHRENIA RESEARCH
    27. Cabeza, IG; Amador, MS; Lopez, CA; de Chavez, MG
      Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors

      SCHIZOPHRENIA RESEARCH
    28. Ramadan, FH; Naughton, BJ; Bassanelli, AG
      Treatment of verbal agitation with a selective serotonin reuptake inhibitor

      JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
    29. Staedt, J; Dewes, D; Danos, P; Stoppe, G
      Can chronic neuroleptic treatment promote sleep disturbances in elderly schizophrenic patients?

      INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
    30. Basan, A; Pitschel-Walz, G; Bauml, J
      Psychoeducational intervention for schizophrenic patients and subsequent long-term treatment: A 4-year follow-up study

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    31. Naidu, PS; Kulkarni, SK
      Differential role of dopamine D-1 and D-2 receptors in isoniazid-induced vacuous chewing movements

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    32. Hernandez, I; Sokolov, BP
      Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment

      JOURNAL OF NEUROSCIENCE RESEARCH
    33. Van Kampen, JM; Stoessl, AJ
      Dopamine D-1A receptor function in a rodent model of tardive dyskinesia

      NEUROSCIENCE
    34. Shapiro, J; Belmaker, RH; Biegon, A; Seker, A; Agam, G
      Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients

      JOURNAL OF NEURAL TRANSMISSION
    35. Sweet, RA; Pollock, BG; Mulsant, BH; Rosen, J; Sorisio, D; Kirshner, M; Henteleff, R; DeMichele, MAA
      Pharmacologic profile of perphenazine's metabolites

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    36. Berardi, D; Giannelli, A; Barnes, TRE
      Clinical correlates of akathisia in acute psychiatric inpatients

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    37. Colonna, L; Saleem, P; Dondey-Nouvel, L; Rein, W
      Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    38. Wahlbeck, K; Nikkila, H; Rimon, R; Ahokas, A
      Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients

      PSYCHIATRY RESEARCH
    39. McConville, BJ; Arvanitis, LA; Thyrum, PT; Yeh, C; Wilkinson, LA; Chaney, RO; Foster, KD; Sorter, MT; Friedman, LM; Brown, KL; Heubi, JE
      Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders

      JOURNAL OF CLINICAL PSYCHIATRY
    40. Teri, L; Logsdon, RG; Peskind, E; Raskind, M; Weiner, MF; Tractenberg, RE; Foster, NL; Schneider, LS; Sano, M; Whitehouse, P; Tariot, P; Mellow, AM; Auchus, AP; Grundman, M; Thomas, RG; Schafer, K; Thal, LJ
      Treatment of agitation in AD - A randomized, placebo-controlled clinical trial

      NEUROLOGY
    41. Holtom, PE; Needham, PL; Bennett, GW; Aspley, S
      Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions

      BRITISH JOURNAL OF PHARMACOLOGY
    42. Schwarz, MJ; Riedel, M; Ackenheil, M; Muller, N
      Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) inunmedicated and medicated schizophrenic patients

      BIOLOGICAL PSYCHIATRY
    43. Sachdev, PS
      The current status of tardive dyskinesia

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
    44. Silvestri, S; Seaman, MV; Negrete, JC; Houle, S; Shammi, CM; Remington, GJ; Kapur, S; Zipursky, RB; Wilson, AA; Christensen, BK; Seeman, P
      Increased dopamine D-2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

      PSYCHOPHARMACOLOGY
    45. Gitlin, MJ; Nuechterlein, KH; Mintz, J; Fogelson, D; Bartzokis, G; Ventura, J; Subotnik, K; Aravagiri, M
      Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression

      PSYCHOPHARMACOLOGY
    46. Saito, H; Saijo, T
      Maintenance therapy

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    47. Madhusoodanan, S; Brenner, R; Cohen, CI
      Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia

      CNS DRUGS
    48. van Vugt, JPP; Roos, RAC
      Huntington's disease - Options for controlling symptoms

      CNS DRUGS
    49. Chanpattana, W; Chakrabhand, S; Sackeim, HA; Kitaroonchai, W; Kongsakon, R; Techakasem, P; Buppanharun, W; Tuntirungsee, Y; Kirdcharoen, N
      Continuation ECT in treatment-resistant schizophrenia: A controlled study

      JOURNAL OF ECT
    50. Chanpattana, W
      Maintenance ECT in mentally retarded, treatment-resistant schizoprenic patients

      JOURNAL OF ECT
    51. Massie, J; Lewis, S
      Duration of treatment in schizophrenia

      JOURNAL OF FORENSIC PSYCHIATRY
    52. Ohmori, T; Ito, K; Abekawa, T; Koyama, T
      Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    53. Muller, N; Riedel, M; Ackenheil, M; Schwarz, MJ
      The role of immune function in schizophrenia: an overview

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    54. Obuchowicz, E; Turchan, J
      Clozapine decreases neuropeptide Y-like immunoreactivity and neuropeptide Y mRNA levels in rat nucleus accumbens

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    55. Obuchowicz, E; Turchan, J
      Effects of acute or long-term treatment with chlorpromazine, haloperidol or sulpiride on neuropeptide Y-like immunoreactivity concentrations in the nucleus accumbens of rat

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    56. Peralta, V; Cuesta, MJ
      Negative, parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited

      SCHIZOPHRENIA RESEARCH
    57. Petty, RG
      Prolactin and antipsychotic medications: mechanism of action

      SCHIZOPHRENIA RESEARCH
    58. Marder, SR
      Antipsychotic drugs and relapse prevention

      SCHIZOPHRENIA RESEARCH
    59. Schwartz, BD; Maron, BA; Evans, WJ; Winstead, DK
      Smooth pursuit tracking deficits of patients with schizophrenia at specific within-sine wave bins

      NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY
    60. Antkiewicz-Michaluk, L; Krygowska-Wajs, A; Michaluk, J; Romanska, I; Szczudlik, A; Vetulani, J
      Plasticity of extrapyramidal dopamine system in Parkinson's disease - A postmortem study

      NEUROSCIENCE RESEARCH COMMUNICATIONS
    61. Tandon, R; Taylor, SF; DeQuardo, JR; Eiser, A; Jibson, MD; Goldman, M
      The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles

      NEUROPSYCHOPHARMACOLOGY
    62. Kelley, ME; Yao, JK; van Kammen, DP
      Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia

      NEUROPSYCHOPHARMACOLOGY
    63. Vauth, R; Dreher-Rudolph, M; Stieglitz, RD
      Integrated treatment of persistent (primary) negative symptoms in schizophrenia

      FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE
    64. Laufer, N; Spivak, B; Holdengreber, V; Zipser, J; Kosower, N; Ragolsky, M; Weizman, A
      H-3-spiperone binding to lymphocytes in neuroleptic-naive-schizophrenia and the effect of neuroleptic treatment

      CLINICAL NEUROPHARMACOLOGY
    65. MESHUL CK; EMRE N; NAKAMURA CM; ALLEN C; DONOHUE MK; BUCKMAN JF
      TIME-DEPENDENT CHANGES IN STRIATAL GLUTAMATE SYNAPSES FOLLOWING A 6-HYDROXYDOPAMINE LESION

      Neuroscience
    66. Ikeda, H; Adachi, K; Hasegawa, M; Sato, M; Hirose, J; Koshikawa, N; Cools, AR
      Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia

      JOURNAL OF NEURAL TRANSMISSION
    67. Rosengarten, H; Schweitzer, JW; Friedhoff, AJ
      The effect of novel antipsychotics in rat oral dyskinesia

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    68. Mauri, MC; Bitetto, A; Fabiano, L; Laini, V; Steinhilber, C; Fornier, M; Rafique, F
      Depressive symptoms and schizophrenic relapses: The effect of four neuroleptic drugs

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    69. Kondo, T; Otani, K; Tokinaga, N; Ishida, M; Yasui, N; Kaneko, S
      Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    70. Lapierre, YD; Angus, C; Awad, AG; Saxena, BM; Jones, B; Williamson, P; Vincent, P; Carle, R; Lavallee, YJ; Manchanda, R; Gauthier, B; Wolf, MA; Teehan, MD; Denis, JF; Malla, AK; Oyewumi, LK; Busse, E; Labelle, A; Claesson, L; Grafford, K
      The treatment of negative symptoms: a clinical and methodological study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    71. Nakaya, M; Suwa, H; Komahashi, T; Ohmori, K
      Is schizophrenic symptomatology independent of the phase of the illness?

      PSYCHOPATHOLOGY
    72. Brune, M
      The incidence of akathisia in bipolar affective disorder treated with neuroleptics - a preliminary report

      JOURNAL OF AFFECTIVE DISORDERS
    73. Adli, M; Rossius, W; Bauer, M
      Olanzapine in the treatment of depressive disorders with psychotic symptoms

      NERVENARZT
    74. Salvador, MTG; Lopez, CA; Lyketsos, CG
      Treatment of agitation in dementia patients

      MEDICINA CLINICA
    75. Lee, H; Tarazi, FI; Chakos, M; Wu, HW; Redmond, M; Alvir, JM; Kinon, BJ; Bilder, R; Creese, I; Lieberman, JA
      Effects of chronic treatment with typical and atypical antipsychotic drugson the rat striatum

      LIFE SCIENCES
    76. Andine, P; Widermark, N; Axelsson, R; Nyberg, G; Olofsson, U; Martensson, E; Sandberg, M
      Characterization of MK-801-induced behavior as a putative rat model of psychosis

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    77. Tandon, R
      Cholinergic aspects of schizophrenia

      BRITISH JOURNAL OF PSYCHIATRY
    78. Amin, F; Silverman, JM; Siever, LJ; Smith, CJ; Knott, PJ; Davis, KL
      Genetic antecedents of dopamine dysfunction in schizophrenia

      BIOLOGICAL PSYCHIATRY
    79. Adityanjee; Aderibigbe, YA; Jampala, VC; Mathews, T
      The current status of tardive dystonia

      BIOLOGICAL PSYCHIATRY
    80. Smedh, K; Spigset, O; Allard, P; Mjorndal, T; Adolfsson, R
      Platelet [H-3]paroxetine and [H-3]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy

      BIOLOGICAL PSYCHIATRY
    81. Richards, SS; Hendrie, HC
      Diagnosis, management, and treatment of Alzheimer disease - A guide for the internist

      ARCHIVES OF INTERNAL MEDICINE
    82. Kelley, ME; van Kammen, DP; Allen, DN
      Empirical validation of primary negative symptoms: Independence from effects of medication and psychosis

      AMERICAN JOURNAL OF PSYCHIATRY
    83. Potkin, SG; Jin, Y; Bunney, BG; Costa, J; Gulasekaram, B
      Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    84. GOFF DC; EVINS AE
      NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - NEUROBIOLOGICAL MODELS AND TREATMENT RESPONSE

      Harvard review of psychiatry
    85. LAVRETSKY H; SULTZER D
      A STRUCTURED TRIAL OF RISPERIDONE FOR THE TREATMENT OF AGITATION IN DEMENTIA

      The American journal of geriatric psychiatry
    86. STEFFENS DC; TUPLER LA; RANGA K; KRISHNAN R
      MAGNETIC-RESONANCE-IMAGING SIGNAL HYPOINTENSITY AND IRON CONTENT OF PUTAMEN NUCLEI IN ELDERLY DEPRESSED-PATIENTS

      PSYCHIATRY RESEARCH-NEUROIMAGING
    87. HEIMBERG C; KOMOROSKI RA; LAWSON WB; CARDWELL D; KARSON CN
      REGIONAL PROTON MAGNETIC-RESONANCE SPECTROSCOPY IN SCHIZOPHRENIA AND EXPLORATION OF DRUG EFFECT

      PSYCHIATRY RESEARCH-NEUROIMAGING
    88. KORTE S; AROLT V; PETERS M; WEITZSCH C; ROTHERMUNDT M; KIRCHNER H
      INCREASED SERUM NEOPTERIN LEVELS IN ACUTELY ILL AND RECOVERED SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    89. GAO XM; SAKAI K; TAMMINGA CA
      CHRONIC OLANZAPINE OR SERTINDOLE TREATMENT RESULTS IN REDUCED ORAL CHEWING MOVEMENTS IN RATS COMPARED TO HALOPERIDOL

      Neuropsychopharmacology
    90. TAMMINGA CA
      SCHIZOPHRENIA AND GLUTAMATERGIC TRANSMISSION

      Critical reviews in neurobiology
    91. MIJNSTER MJ; SCHOTTE A; DOCTOR GJ; VOORN P
      EFFECTS OF RISPERIDONE AND HALOPERIDOL ON TACHYKININ AND OPIOID PRECURSOR PEPTIDE MESSENGER-RNA LEVELS IN THE CAUDATE-PUTAMEN AND NUCLEUS-ACCUMBENS OF THE RAT

      Synapse
    92. SACHDEV P
      TARDIVE BLEPHAROSPASM

      Movement disorders
    93. KOMPOLITI K; GOETZ CG
      HYPERKINETIC MOVEMENT-DISORDERS MISDIAGNOSED AS TICS IN GILLES-DE-LA-TOURETTE-SYNDROME

      Movement disorders
    94. FINKEL SI
      ANTIPSYCHOTICS - OLD AND NEW

      Clinics in geriatric medicine
    95. CSERNANSKY JG; BARDGETT ME
      LIMBIC-CORTICAL NEURONAL DAMAGE AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA

      Schizophrenia bulletin
    96. ULRICH S; WURTHMANN C; BROSZ M; MEYER FP
      THE RELATIONSHIP BETWEEN SERUM CONCENTRATION AND THERAPEUTIC EFFECT OF HALOPERIDOL IN PATIENTS

      Clinical pharmacokinetics
    97. LINSZEN DH; DINGEMANS PMAJ; LENIOR ME; SCHOLTE WF; DEHAAN L; GOLDSTEIN MJ
      EARLY DETECTION AND INTERVENTION IN SCHIZOPHRENIA

      International clinical psychopharmacology
    98. ANDERSSON C; CHAKOS M; MAILMAN R; LIEBERMAN J
      EMERGING ROLES FOR NOVEL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA

      The Psychiatric clinics of North America
    99. SASAKI T; KENNEDY JL; NOBREGA JN
      REGIONAL BRAIN CHANGES IN [H-3]SCH-23390 BINDING TO DOPAMINE D1, RECEPTORS AFTER LONG-TERM HALOPERIDOL TREATMENT - LACK OF CORRESPONDENCE WITH THE DEVELOPMENT OF VACUOUS CHEWING MOVEMENTS

      Behavioural brain research
    100. LAMPREAVE JL; MOLINA V; MARDOMINGO MJ; BITTINI A; DOMINGUEZ P; ALMOGUERA I; RUBIA FJ; CARRERAS JL
      TECHNETIUM-99M-HMPAO IN TOURETTES-SYNDROME ON NEUROLEPTIC THERAPY ANDAFTER WITHDRAWAL

      The Journal of nuclear medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/06/20 alle ore 02:09:50